David Ovalle

Author's posts

Amid overdose crisis, disputes grow over how to classify fentanyl cousins

With frustration mounting about the toll of fentanyl, the debate over analogues has sparked clashing political approaches.

Governments get nearly $19 billion more in opioid lawsuit settlements

The money comes from pharmacy chains and drug manufacturers to settle lawsuits over their roles in flooding the United States with painkillers.

Opioid distributor, already facing license revocation, sued by tribe

The Cherokee Nation is suing Morris & Dickson, one of the nation’s largest drug distributors.

Appeals court paves way for Purdue Pharma opioids settlement

The ruling also shields from future claims members of the Sackler family, who own Purdue Pharma.

New overdose antidote approved. Concerns raised about cost, side effects

The drug Opvee joins a growing market of overdose-reversing medications at a critical juncture in the nation’s drug crisis.

There’s medicine to quiet his opioid cravings. Getting it can be hard.

One man’s plight illustrates challenges faced by those with opioid addiction — especially people of color — in getting buprenorphine, an anti-addiction drug.

U.S. overdose deaths plateau in 2022, but still exceed 100,000

In 2022, opioids, including fentanyl, accounted for nearly 80,000 of the overdose deaths.

Do overdose prevention centers work? First U.S. study seeks answers

Federally funded study will look at whether those using drugs in programs in New York City and Rhode Island are less likely to overdose.

Overdose prevention centers are tough sell in U.S. despite successes

The supervised injection sites allow people to take illegal drugs like fentanyl under watch of staff trained to reverse overdoses.

Artist’s death spotlights peril posed by xylazine-fentanyl mix

‘It’s all designed to kill,’ says grieving brothe of the noxious substances added to illicit drugs without users’ knowledge.